On October 10, 2025, President Donald Trump announced a deal with AstraZeneca to lower drug prices for Medicaid patients by matching the lowest prices in developed countries. The agreement includes AstraZeneca's commitment to invest $50 billion in U.S. manufacturing by 2030 and participation in the upcoming TrumpRx website, which will sell discounted drugs directly to consumers starting in early 2026.